Van Lanschot Kempen Investment Management N.V. Boosts Stock Position in Danaher Corporation $DHR

Van Lanschot Kempen Investment Management N.V. boosted its stake in shares of Danaher Corporation (NYSE:DHR) by 1.4% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 595,678 shares of the conglomerate’s stock after buying an additional 8,416 shares during the period. Danaher makes up about 1.2% of Van Lanschot Kempen Investment Management N.V.’s investment portfolio, making the stock its 23rd largest holding. Van Lanschot Kempen Investment Management N.V.’s holdings in Danaher were worth $136,363,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also added to or reduced their stakes in the stock. L1 Capital International Pty Ltd grew its stake in shares of Danaher by 304.5% in the fourth quarter. L1 Capital International Pty Ltd now owns 400,246 shares of the conglomerate’s stock worth $91,624,000 after acquiring an additional 301,308 shares during the last quarter. Banco Santander S.A. raised its position in shares of Danaher by 14.6% in the 4th quarter. Banco Santander S.A. now owns 14,322 shares of the conglomerate’s stock worth $3,279,000 after purchasing an additional 1,825 shares during the last quarter. Lord Abbett & CO. LLC boosted its stake in Danaher by 307.1% in the 4th quarter. Lord Abbett & CO. LLC now owns 698,256 shares of the conglomerate’s stock worth $159,845,000 after purchasing an additional 526,732 shares in the last quarter. Clal Insurance Enterprises Holdings Ltd boosted its stake in Danaher by 71.6% in the 4th quarter. Clal Insurance Enterprises Holdings Ltd now owns 127 shares of the conglomerate’s stock worth $29,000 after purchasing an additional 53 shares in the last quarter. Finally, Klingenstein Fields & Co. LP grew its position in Danaher by 0.3% during the 4th quarter. Klingenstein Fields & Co. LP now owns 55,930 shares of the conglomerate’s stock valued at $12,803,000 after purchasing an additional 160 shares during the last quarter. Hedge funds and other institutional investors own 79.05% of the company’s stock.

More Danaher News

Here are the key news stories impacting Danaher this week:

• Positive Sentiment: Danaher closed its $9.9 billion acquisition of Masimo, expanding its diagnostics and patient-monitoring portfolio with AI-enabled sensor technologies that could support longer-term growth. Danaher Boosts Product Portfolio With the Acquisition of Masimo
• Positive Sentiment: Cepheid, a Danaher company, donated Xpert Hemorrhagic Fever panel tests to support Ebola outbreak response in Africa, highlighting the company’s diagnostic relevance and public-health role. Cepheid Delivers Xpert Hemorrhagic Fever Panel Tests to Africa
• Positive Sentiment: Analysts noted strong performance in Danaher’s biotechnology unit, with bioprocessing demand and equipment orders rising, which supports the company’s 2026 growth outlook. Strong Performance Continues at DHR’s Biotechnology Unit: What’s Next?

Analysts Set New Price Targets

DHR has been the subject of a number of analyst reports. Morgan Stanley reduced their price objective on shares of Danaher from $270.00 to $255.00 and set an “overweight” rating for the company in a research note on Wednesday, April 22nd. Piper Sandler initiated coverage on shares of Danaher in a report on Thursday. They set a “neutral” rating and a $200.00 price target on the stock. Wall Street Zen downgraded shares of Danaher from a “buy” rating to a “hold” rating in a research report on Saturday, April 25th. Evercore boosted their price objective on shares of Danaher from $225.00 to $232.00 and gave the stock an “outperform” rating in a report on Tuesday, April 21st. Finally, UBS Group lowered their price objective on Danaher from $270.00 to $250.00 and set a “buy” rating on the stock in a research report on Wednesday, April 22nd. One research analyst has rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and five have issued a Hold rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $233.61.

Danaher Price Performance

Shares of NYSE:DHR opened at $179.95 on Friday. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.52 and a current ratio of 1.87. The firm has a market cap of $127.37 billion, a price-to-earnings ratio of 34.81, a price-to-earnings-growth ratio of 2.41 and a beta of 0.81. The business has a 50-day simple moving average of $180.93 and a two-hundred day simple moving average of $204.78. Danaher Corporation has a fifty-two week low of $160.93 and a fifty-two week high of $242.80.

Danaher (NYSE:DHR) last announced its quarterly earnings results on Monday, April 20th. The conglomerate reported $2.06 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.94 by $0.12. Danaher had a net margin of 14.89% and a return on equity of 10.91%. The firm had revenue of $5.95 billion for the quarter, compared to the consensus estimate of $6 billion. During the same quarter last year, the firm posted $1.88 EPS. The business’s quarterly revenue was up 3.7% compared to the same quarter last year. On average, analysts expect that Danaher Corporation will post 8.45 earnings per share for the current year.

Danaher Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, July 31st. Investors of record on Friday, June 26th will be issued a $0.40 dividend. The ex-dividend date is Friday, June 26th. This represents a $1.60 annualized dividend and a yield of 0.9%. Danaher’s dividend payout ratio (DPR) is currently 30.95%.

Danaher Profile

Danaher Corporation (NYSE: DHR) is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.

Products and services in Danaher’s portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.